CAMP4 Reports Third Quarter 2024 Financial Results
CAMP4 Therapeutics reported Q3 2024 financial results and corporate updates. The company completed an IPO raising $82.1M in gross proceeds. Key highlights include completing the Single Ascending Dose portion of Phase 1 study for CMP-CPS-001, with safety data expected in Q1 2025, and entering a strategic collaboration with BioMarin valued at over $370M. The company reported a net loss of $13.5M for Q3 2024, with R&D expenses at $9.7M and G&A expenses at $3.8M. Cash position was $2.5M at quarter-end, strengthened by the IPO proceeds.
CAMP4 Therapeutics ha riportato i risultati finanziari del terzo trimestre 2024 e aggiornamenti aziendali. L'azienda ha completato un'IPO raccogliendo 82,1 milioni di dollari in proventi lordi. I punti salienti includono il completamento della parte a dose ascendente singola dello studio di Fase 1 per CMP-CPS-001, con dati sulla sicurezza attesi nel primo trimestre del 2025, e l'ingresso in una collaborazione strategica con BioMarin del valore di oltre 370 milioni di dollari. L'azienda ha riportato una perdita netta di 13,5 milioni di dollari per il terzo trimestre 2024, con spese R&D pari a 9,7 milioni di dollari e spese G&A pari a 3,8 milioni di dollari. La posizione di cassa era di 2,5 milioni di dollari alla fine del trimestre, rafforzata dai proventi dell'IPO.
CAMP4 Therapeutics informó los resultados financieros del tercer trimestre de 2024 y actualizaciones corporativas. La empresa completó una oferta pública inicial (IPO) recibiendo 82,1 millones de dólares en ingresos brutos. Los aspectos destacados incluyen la finalización de la parte de dosis ascendente única del estudio de Fase 1 para CMP-CPS-001, con datos de seguridad esperados para el primer trimestre de 2025, y la entrada en una colaboración estratégica con BioMarin valorada en más de 370 millones de dólares. La empresa reportó una pérdida neta de 13,5 millones de dólares para el tercer trimestre de 2024, con gastos de I+D de 9,7 millones de dólares y gastos generales y administrativos de 3,8 millones de dólares. La posición de efectivo era de 2,5 millones de dólares al final del trimestre, fortalecida por los ingresos de la IPO.
CAMP4 Therapeutics는 2024년 3분기 재무 결과 및 기업 업데이트를 보고했습니다. 이 회사는 8,210만 달러의 총 수익을 올리며 IPO를 완료했습니다. 주요 하이라이트로는 CMP-CPS-001의 1상 시험에서 단일 용량 상승 부분을 완료한 것이 있으며, 안전성 데이터는 2025년 1분기에 예상됩니다. 또한 BioMarin과 3억 7천만 달러 이상의 가치가 있는 전략적 협력 관계를 맺었습니다. 회사는 2024년 3분기에 1,350만 달러의 순손실을 보고했으며, 연구 및 개발 비용은 970만 달러, 일반 관리 비용은 380만 달러였습니다. 분기 말 현금 보유액은 250만 달러였으며, IPO 수익으로 강화되었습니다.
CAMP4 Therapeutics a reporté les résultats financiers du troisième trimestre 2024 et des mises à jour d'entreprise. La société a complété une introduction en bourse (IPO) en levant 82,1 millions de dollars de produits bruts. Les points saillants incluent l'achèvement de la partie dose unique ascendante de l'étude de Phase 1 pour CMP-CPS-001, avec des données de sécurité attendues au premier trimestre 2025, et la signature d'une collaboration stratégique avec BioMarin d'une valeur de plus de 370 millions de dollars. L'entreprise a enregistré une perte nette de 13,5 millions de dollars pour le troisième trimestre 2024, avec des dépenses en R&D de 9,7 millions de dollars et des dépenses générales et administratives de 3,8 millions de dollars. La position de trésorerie était de 2,5 millions de dollars à la fin du trimestre, renforcée par les produits de l'IPO.
CAMP4 Therapeutics hat die Finanzergebnisse für das dritte Quartal 2024 und Unternehmensupdates berichtet. Das Unternehmen hat einen Börsengang (IPO) abgeschlossen und dabei 82,1 Millionen Dollar in Bruttoerlösen eingesammelt. Zu den wichtigsten Highlights gehört der Abschluss des Abschnitts zur einzelnen aufsteigenden Dosis der Phase-1-Studie für CMP-CPS-001, wobei Sicherheitsdaten im ersten Quartal 2025 erwartet werden, und der Eintritt in eine strategische Zusammenarbeit mit BioMarin, die auf über 370 Millionen Dollar geschätzt wird. Das Unternehmen meldete für das dritte Quartal 2024 einen Nettoverlust von 13,5 Millionen Dollar, mit F&E-Ausgaben in Höhe von 9,7 Millionen Dollar und allgemeinen Verwaltungskosten von 3,8 Millionen Dollar. Die Cash-Position betrug am Quartalsende 2,5 Millionen Dollar, gestärkt durch die Erlöse des IPO.
- Successfully completed IPO raising $82.1M in gross proceeds
- Secured strategic collaboration with BioMarin valued at over $370M
- Received FDA Orphan Drug Designation and Rare Pediatric Disease Designation for CMP-CPS-001
- Completed Single Ascending Dose portion of Phase 1 study
- Net loss increased to $13.5M in Q3 2024 from $11.7M in Q3 2023
- G&A expenses increased to $3.8M from $2.9M year-over-year
- Low cash position of $2.5M at quarter-end before IPO proceeds
Insights
The Q3 results reveal significant financial developments for CAMP4, with the standout being their successful
Q3 financials show controlled R&D spending at
The completion of the Single Ascending Dose portion of the Phase 1 trial for CMP-CPS-001 marks a important milestone. The upcoming safety data in Q1 2025 and Multiple Ascending Dose biomarker efficacy data in H2 2025 are key catalysts that could accelerate the path to a registrational Phase 2/3 study. The FDA's Orphan Drug and Rare Pediatric Disease Designations for urea cycle disorders treatment strengthen the program's market potential.
The BioMarin collaboration validates CAMP4's RNA Actuating Platform technology, potentially expanding their therapeutic reach in rare genetic conditions. This partnership, combined with their novel regRNA-targeting approach, positions them uniquely in the genetic disease treatment landscape.
- Completed Initial Public Offering (IPO) of common stock, raising gross proceeds of
- Single Ascending Dose (SAD) portion of Phase 1 study of CMP-CPS-001 completed; safety data anticipated in Q1 2025
- Entered strategic research collaboration with BioMarin valued at over
CAMBRIDGE, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update.
“The third quarter of 2024 has been transformational for CAMP4, highlighted by our successful IPO and continued strong progress with our lead program, CMP-CPS-001, which received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA, underscoring its potential as a novel therapeutic candidate for the treatment of urea cycle disorders,” said Josh Mandel-Brehm, Chief Executive Officer of CAMP4. “We also partnered with BioMarin to identify novel therapeutics targeting regRNAs associated with genetic diseases, validating the potential of our RNA Actuating Platform and reinforcing our commitment to advance cutting-edge solutions for patients in need.”
Mr. Mandel-Brehm continued, “We continue to advance our CMP-CPS-001 program through the Phase 1 trial, and we anticipate reporting SAD safety data in the first quarter of 2025 followed by multiple ascending dose (MAD) biomarker efficacy data in the second half of 2025, that may enable a registrational Phase 2/3 study. With the proceeds from our IPO, we are well positioned to support continued clinical and preclinical development of our ongoing programs.”
Recent Corporate Highlights:
- In October 2024, CAMP4 completed its IPO of 6,820,000 shares of its common stock at an initial public offering price of
$11.00 per share. Aggregate gross proceeds to CAMP4 were approximately$75.0 million . The underwriters also partially exercised their option to purchase an additional 643,762 shares of common stock for total offering gross proceeds of$82.1 million . - Entered strategic research collaboration agreement with BioMarin to leverage CAMP4’s RAP Platform™ to identify and advance regRNAs for rare genetic conditions. CAMP4 is eligible to receive upfront and milestone payments in addition to tiered royalties.
- The FDA granted RPDD and ODD to CMP-CPS-001 for the treatment of UCDs.
- Ongoing Phase 1 clinical trial of CMP-CPS-001 in UCDs, with dosing completed for all SAD cohorts. The Phase 1 study is a randomized, double-blind, and placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetics of CMP-CPS-001 in 96 healthy volunteers. The company anticipates reporting SAD safety data in the first quarter of 2025 followed by MAD safety, pharmacokinetic and pharmacodynamic biomarker efficacy data in the second half of 2025.
Third Quarter 2024 Financial Results
CAMP4 ended the third quarter with
Research and Development (R&D) expenses were
General and administrative (G&A) expenses were
Net loss was
About CAMP4 Therapeutics
CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regRNAs, which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform™ enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. Learn more about us at www.CAMP4tx.com and follow us on LinkedIn and X.
Forward-Looking Statements
This press release contains forward-looking statements which involve risks, uncertainties and contingencies, many of which are beyond the control of the Company, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning CAMP4’s plans, objectives, expectations and intentions; the timing and results of ongoing and future clinical trials, including expectations on the timing of reporting SAD and MAD data from and seeking regulatory approval for the CMP-CPS-001 trial; its growth strategy; and cash balance guidance. The forward-looking statements in this press release speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions that could cause the Company’s actual results to differ materially from those anticipated in the forward-looking statements, including, but not limited to: the Company’s limited operating history, incurrence of substantial losses since the Company’s inception and anticipation of incurring substantial and increasing losses for the foreseeable future; the Company’s need for substantial additional financing to achieve the Company’s goals; the uncertainty of clinical development, which is lengthy and expensive, and characterized by uncertain outcomes, and risks related to additional costs or delays in completing, or failing to complete, the development and commercialization of the Company’s current product candidates or any future product candidates; delays or difficulties in the enrollment and dosing of patients in clinical trials; the impact of any significant adverse events or undesirable side effects caused by the Company’s product candidates; potential competition, including from large and specialty pharmaceutical and biotechnology companies; the Company’s ability to realize the benefits of the Company’s current or future collaborations or licensing arrangements and ability to successfully consummate future partnerships; the Company’s ability to obtain regulatory approval to commercialize any product candidate in the United States or any other jurisdiction, and the risk that any such approval may be for a more narrow indication than the Company seeks; the Company’s dependence on the services of the Company’s senior management and other clinical and scientific personnel, and the Company’s ability to retain these individuals or recruit additional management or clinical and scientific personnel; the Company’s ability to grow the Company’s organization, and manage the Company’s growth and expansion of the Company’s operations; risks related to the manufacturing of the Company’s product candidates, which is complex, and the risk that the Company’s third-party manufacturers may encounter difficulties in production; the Company’s ability to obtain and maintain sufficient intellectual property protection for the Company’s product candidates or any future product candidates the Company may develop; the Company’s reliance on third parties to conduct the Company’s preclinical studies and clinical trials; the Company’s compliance with the Company’s obligations under the licenses granted to the Company by others, for the rights to develop and commercialize the Company’s product candidates; risks related to the operations of the Company’s suppliers; and other risks and uncertainties described in the section “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, as well as other information we file with the Securities and Exchange Commission. The forward-looking statements in this press release are inherently uncertain and are not guarantees of future events. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond the Company’s control, you should not unduly rely on these forward-looking statements. The events and circumstances reflected in the forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Moreover, the Company operates in an evolving environment. New risks and uncertainties may emerge from time to time, and management cannot predict all risks and uncertainties. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. Except as required by applicable law, the Company does not undertake to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contacts
Investor Relations:
Sandya von der Weid
LifeSci Advisors
svonderweid@lifesciadvisors.com
Media:
Jason Braco, Ph.D.
LifeSci Communications
jbraco@lifescicomms.com
| CAMP4 Therapeutics Corporation Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (In thousands, except for share and per share data) | ||||||||||||||
| Three months ended September 30, | Nine months ended September 30, | |||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||
| (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | |||||||||||
| Revenue | ||||||||||||||
| Research and collaboration revenue | $ | - | $ | 350 | $ | - | $ | 350 | ||||||
| Operating Expenses: | ||||||||||||||
| Research and development | 9,702 | 9,819 | 28,821 | 29,955 | ||||||||||
| General and administrative | 3,814 | 2,869 | 10,233 | 8,798 | ||||||||||
| Total operating expenses | 13,516 | 12,688 | 39,054 | 38,753 | ||||||||||
| Loss from operations | (13,516 | ) | (12,338 | ) | (39,054 | ) | (38,403 | ) | ||||||
| Other income (expense), net: | ||||||||||||||
| Interest income | 94 | 689 | 720 | 2,239 | ||||||||||
| Other expense | (62 | ) | (47 | ) | (178 | ) | (137 | ) | ||||||
| Total other income, net | 32 | 642 | 542 | 2,102 | ||||||||||
| Net loss attributable to common stockholders and comprehensive loss | $ | (13,484 | ) | $ | (11,696 | ) | $ | (38,512 | ) | $ | (36,301 | ) | ||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (24.19 | ) | $ | (29.21 | ) | $ | (76.50 | ) | $ | (94.62 | ) | ||
| Weighted-average shares of common stock outstanding, basic and diluted | 557,437 | 400,426 | 503,455 | 383,653 | ||||||||||
| Condensed Balance Sheet Data: | September 30, | December 31, | ||||||
| (in thousands) | 2024 | 2023 | ||||||
| Cash and cash equivalents | $ | 2,528 | $ | 38,380 | ||||
| Working capital(1) | (6,325 | ) | 32,206 | |||||
| Total assets | 21,364 | 54,946 | ||||||
| Total liabilities | 18,192 | 16,529 | ||||||
| Convertible preferred stock | 162,147 | 162,147 | ||||||
| Accumulated deficit | (198,474 | ) | (159,962 | ) | ||||
| Total stockholders’ deficit | (158,975 | ) | (123,730 | ) | ||||
(1) Working capital is defined as total current assets less total current liabilities. See our condensed consolidated financial statements and the related notes thereto included in our Quarterly Report on Form 10-Q for the period ended September 30, 2024 for further details regarding our current assets and current liabilities.
FAQ
What were CAMP4's Q3 2024 financial results?
How much did CAMP4 raise in its IPO?
When will CAMP4 report safety data for CMP-CPS-001?
